Unum Therapeutics, Inc.

Unum Therapeutics, Inc.

Unum Therapeutics, Inc.

Overview
Date Founded

2014

Headquarters

200 Cambridge Park Drive, Suite 3100, Cambridge, MA, 02140, USA

Type of Company

Public

Employees (Worldwide)

72

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Unum Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President, Chief Executive Officer & Director

Chief Technical Officer & Senior Vice President-Operations

Chief Medical Officer

Vice President, Head of Quality

Head of Research

Head of Business & Corporate Development

Vice President, Head of People

Vice President, Head of Program Leadership & Portfolio Management

Vice President, Regulatory Affairs

Vice President, Technical Operations

Board of Directors

Co-Founder at Rodin Therapeutics, Inc.

Chief Executive Officer at Willow Advisors LLC

Former Chief Operating Officer at Epizyme, Inc.

Former Head-Oncology Therapeutic Area at Takeda Oncology Co.

Chief Executive Officer & Director at Hookipa Pharma, Inc.

Founder, President, Chief Executive Officer & Director at Unum Therapeutics, Inc.

Paths to Unum Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Unum Therapeutics, Inc.
Recent Transactions
Details Hidden

Unum Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Unum Therapeutics, Inc. raised money in a private placement transaction

Advisors & Consultants
Consultant

Medical Oncology at Dana-Farber Cancer Institute, Inc.

Advisor

Senior Vice President at Stern Investor Relations, Inc.

Clients

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Key Stats and Financials As of 2019
Market Capitalization
$10.8M
Total Enterprise Value
$-9.44M
Earnings Per Share
$-1.04
Revenue
$22.5M
EBITDAMargin
-137.27%
EBITDA
$-30.9M
Total Equity
$31.8M
Total Debt
$6.03M
Net Profit
$-31.8M
Enterprise Value Sales
-0.42x
TEVNet Income
0.3x
Debt TEV
-0.64x
Three Year Compounded Annual Growth Rate Of Revenue
52.41%
Investors
Details Hidden

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Details Hidden

Professor, Department of Pediatrics at National University of Singapore

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Suppliers
National University of Singapore Management Consulting | Singapore

National University of Singapore is a global university centered in Asia. It aspires to influence the future by changing the way people think and do things through education, research, and service.

St. Jude Children's Research Hospital, Inc. Medical Support Services | Memphis, TN

St. Jude is unlike any other pediatric treatment and research facility. Discoveries made here have completely changed how the world treats children with cancer and other catastrophic diseases. With research and patient care under one roof, St. Jude is where some of today's most gifted researchers are able to do science more quickly. The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder Danny Thomas, no child is denied treatment based on race, religion or a family's ability to pay. Our vision is to be the world leader in advancing the treatment and prevention of catastrophic diseases in children. This vision will be pursued by providing outstanding patient care; by conducting basic, translational and clinical research designed to elucidate biological mechanisms, understand disease pathogenesis, improve diagnosis, enhance treatment outcome, prevent diseases and minimize adverse consequences of treatment; and by educating health care and scientific research professionals. Through these efforts we seek to cure and enhance the quality of life for an increasing proportion of children who come to us for treatment, and by expanding and sharing knowledge, to advance treatment of children with catastrophic diseases worldwide, while developing strategies to prevent catastrophic diseases in children.

BioLife Solutions Inc. Industrial Machinery & Manufacturing | Bothell, Washington

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Competitors
MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Unum Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Unum Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Unum Therapeutics, Inc..